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Objective: The authors examined the efficacy of valproate to
reduce relapse to heavy drinking among veterans with al-
cohol use disorder (AUD) and neuropsychiatric comorbid-
ities and whether antecedent traumatic brain injury (TBI)
or posttraumatic stress disorder (PTSD) affected treatment
response.
Methods: Participants were male veterans 18–60 years old
with an AUD and no other substance use besides nicotine
or cannabis. Sixty-two patients were randomly assigned to
receive either valproate or naltrexone. Participants were
evaluated at baseline and followed weekly for 24 weeks.
All participants received standardized psychosocial inter-
ventions as well as treatment for coexistent psychiatric
conditions.
Results: During the follow-up period, nine study subjects in
the naltrexone group and 14 in the valproate group relapsed
to heavy drinking, but the difference did not reach statistical
significance. Participants with a history of moderate to se-
vere TBI were more likely to relapse to heavy drinking
compared with those with no TBI (hazard ratio=4.834, 95%
CI=1.103–21.194, p=0.033). PTSD status did not significantly
affect outcome.
Conclusions: Intensive outpatient programs are efficacious
alternatives to treat AUD in veterans, although the role of
pharmacological treatment is not completely elucidated.
Glutamatergic agents appear to be less effective than opi-
ate antagonists to prevent relapse to heavy drinking and to
increase cumulative abstinence. Future studies should ex-
amine novel pharmacological and nonpharmacological
options.
JNCN in Advance (doi: 10.1176/appi.neuropsych.18110250)
The 1-year and lifetime prevalence of alcohol use disorders
(AUD) has been estimated to be 13.9% and 29.1%, re-
spectively, in the adult U.S. civilian population (1). In vet-
erans, the lifetime prevalence of AUDs was estimated to be
32%, whereas estimates of their past-year prevalence vary
between 5% and 21% (2). In addition to this high prevalence,
veterans are vulnerable to develop complex forms of ad-
dictive disorders characterized by the presence of coexistent
psychiatric conditions, particularly posttraumatic stress
disorder (PTSD) and mood disturbance (3). Furthermore,
the high frequency of traumatic brain injury (TBI) among
veterans conveys an additional risk of developing refractory
forms of AUD, probably related to the disruption of pre-
frontal circuits mediating reward expectation, impulse
control, and emotional regulation (4).
A history of TBI is frequently present among clients of
substance abuse treatment programs (5). A recent survey of
7,784 patients enrolled in state-funded treatment programs
in Kentucky showed that 31.7% reported a lifetime history of
one or more TBIs with loss of consciousness. In this sample,
patients with recurrent TBI had more severe psychiatric
problems, more cognitive deficits, and greater impulsivity
(6). Consistent with this report, 36 of 50 seriously ill patients
(72%) admitted to a specialized dual diagnosis programwere
shown to have a history of TBI (7) and had worse treatment
outcomes than patients without TBI (7).
The relationship between TBI and alcohol misuse is bi-
directional. It is well known that alcohol misuse is a risk
factor for TBI, as evidenced by the fact that alcohol in-
toxication is involved in approximately 50% of TBI cases in
civilian settings (8). On the other hand, previous epidemio-
logical studies reported that TBI patients without a history
of misuse have a greater risk of developing AUD than control
subjects during the first 3 years following trauma (9, 10).
TBI is characterized by axonal damage and neuronal loss
in vulnerable regions of the prefrontal cortex (PFC), hip-
pocampus, thalamus, striatum, amygdala, and forebrain nu-
clei (11, 12). AUD may also produce structural and metabolic
changes in these structures (13, 14). It is plausible that TBI
and AUD may act synergistically to disrupt the neural cir-
cuits that mediate stress responses (15, 16), the prefrontal
modulation of emotional processing (17), and critical aspects
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of addictive behavior such as stimulus salience attribution,
reward expectation, and response inhibition (18, 19).
Pharmacological options to treat AUD include naltrexone
(20), acamprosate, and topiramate (21). Of these drugs,
naltrexone is the only one that has been rigorously tested in
the veteran population. Krystal et al. (22) conducted a
multicenter, randomized controlled trial of naltrexone effi-
cacy to treat alcohol dependence in conjunction with stan-
dardized psychosocial treatment among 627 veterans. They
did not find differences between the active drug and placebo
in any of their outcome measures (22). Secondary analysis of
their data, however, suggested that naltrexone can reduce
heavy drinking among alcohol-dependent patients receiving
antidepressants (23).
Anticonvulsants have a role in the treatment of addictive
disorders, probably through their effects on glutamatergic
and GABAergic neurotransmission (24). For example,
Beresford et al. (25), reported retrospective data obtained
through review of medical charts from 18 patients with a
history of TBI, affective lability, and alcohol dependence
treated with mood stabilizing medication for 6 weeks. They
observed beneficial effects of anticonvulsants on emotional
lability and alcohol misuse (25). Previous trials support
valproate’s efficacy to treat alcohol withdrawal (26, 27) and
to prevent relapse after completion of detoxification (27, 28).
In addition, valproate has been shown to be efficacious to
reduce alcohol misuse among patients with coexistent psy-
chiatric disorders (29).
The primary goal of this study was to examine AUD
treatment outcomes in a veteran population with neuro-
psychiatric comorbidities. We hypothesized that veterans
receiving valproate would be less likely to relapse into heavy
drinking than veterans receiving naltrexone. In addition, the
study examined if the antecedent of TBI or the presence of
PTSD affected treatment response.
METHODS
Experimental Design
This was a double-blind active-controlled parallel group
randomized controlled trial. Patients with AUD were eval-
uated at the time of enrollment in outpatient treatment and
followed weekly for 24 weeks. All patients received stan-
dardized psychosocial interventions as well as usual treat-
ment for coexistent psychiatric conditions. In addition, they
were randomly assigned to receive either valproate or nal-
trexone. The study protocol is detailed in the online sup-
plement. The protocol was approved by the institutional
review boards at the University of Iowa and Baylor College
of Medicine. Informed consent was obtained from every
participant.
Study Participants
Participants were male veterans 18–60 years old, with an
AUD and no other substance use besides nicotine or can-
nabis. All study subjects underwent successful detoxification
before starting rehabilitation. Veterans were enrolled in the
outpatient substance abuse treatment programs at two sites:
the Iowa City VA Medical Center and the Michael E.
DeBakey VA Medical Center in Houston. Veterans with
psychotic disorders, significant medical comorbidities (e.g.,
study subjects with moderate to severe heart failure, end-
stage renal disease, or evidence of moderate to advanced
liver disease), and multiple AUD treatment failures (i.e.,
three inpatient residential treatments during the 2 years
before enrollment) were excluded from the study. The ra-
tionale of the last criterion was to prevent excessive attrition
related to the recruitment of extremely refractory patients.
Further details regarding inclusion and exclusion criteria
are provided in the online supplement.
Randomization
Patients who met inclusion criteria were randomly assigned
using a permuted blocks randomization scheme. Treatment
randomization was stratified by psychosocial treatment
frequency, because this might be a major predictor of re-
covery. Thirty-one participants were randomly assigned to
receive valproate, and 31 were assigned to receive an active
control (naltrexone) (Figure 1).
Patients were excluded if they did not meet the drinking
criteria, showed evidence of substance abuse different from
nicotine or cannabis, currently required therapy with val-
proate or naltrexone, had severe complicating medical ill-
ness, or had other/multiple reasons for exclusion (Figure 1).
Primary and Secondary Outcomes
The primary outcome variable was the time to relapse to
heavy drinking, defined by having five or more drinks in a
sitting, and was assessed using the timeline follow-back
method (30). A structured questionnaire reviewed the
amount of alcohol that the patient had consumed on each of
the days of the previous week. Additional outcomes included
time to the first drink as well as the percentage of drinking
weeks during the follow-up period. The evaluation of
drinking outcomes was done by experts from the Iowa
Consortium for Substance Abuse Research and Evaluation.
Information sources were the participants’ report and VA
medical records. Evaluators were not involved in any aspect
of treatment and were blind to the randomized intervention
status.
TBI Assessment
To ascertain TBI, we used the definition provided by the
VA/Department of Defense clinical practice guideline
(https://www.ncbi.nlm.nih.gov/books/NBK189784). TBI was fur-
ther categorized as mild, moderate, or severe based on the
presence and duration of loss of consciousness, the length of
posttraumatic amnesia, and the duration of altered mental
status associated with the event.
Pertinent information was obtained from veterans’ self-
report and review of medical records, including neuro-
imaging reports. Detailed information was generally
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obtained from cases of moderate to severe TBI. However,
this was not true for most veterans suffering mild TBI; we
had to rely in their self-report of the event. If a patient ex-
perienced multiple TBI events of different severity, the
higher severity level was assigned.
Neuropsychiatric Assessment
Diagnosis of comorbid psychiatric conditions was made
using the Mini-International Neuropsychiatric Interview
(31); the severity of depressive, anxiety, and PTSD symptoms
wasmeasured by theHamiltonDepression Rating Scale (32),
the Hamilton Anxiety Rating Scale (33), and the PTSD
Checklist (34). Severity of AUD was assessed through the
Alcohol Use Disorders Identification Test (35). Estimation of
the likelihood that symptoms and functional status of an
individual resulted from lifetime TBI exposure was done
using the Ohio State University TBI Inventory (36).
Psychosocial Intervention
Treatment was based on the Matrix Intensive Outpatient
Drug and Alcohol Treatment Model (Substance Abuse and
Mental Health Services
Administration [SAMHSA]







step facilitation, group ther-
apy and social support, and
individual supportive psy-
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were offered the possibility
of having conventional out-
patient treatment (SAMHSA
level 1) instead of the in-
tensive program. This flexi-
ble approach was adopted
to include those veterans
with AUD who sought re-
habilitation treatment but
had limited time to devote





release tablets were initiated
at a dosage of 250 mg per day, taken approximately 30 min-
utes after a meal. Dosage was increased up to a dose of
1,000 mg per day. We used a fixed dose of valproate to
minimize side effects and increase tolerability within a
population with mild liver abnormalities. Therapeutic levels
of valproate have not been established for the treatment of
AUDs. However, in this study, determination of valproate
levels contributed to the assessment of compliance with the
medication regimen. Naltrexone was given once per day in a
dose of 25 mg for the first 4 days and 50 mg thereafter, up to
completion of the protocol. All naltrexone and valproate pills
were identical in appearance. Compliance was assessed
each week concurrently with the determination of alcohol
consumption.
Adverse Events
An adverse event was defined as any undesirable medical
event with new onset or significant exacerbation during the
study, regardless if it was considered to be related to the
study medication. Adverse events were graded on a three-
point ordinal scale: mild, moderate, and severe. Further
FIGURE 1. CONSORT flow diagram
Assessed for eligibility (N=104)
Randomized (N=70)
Naltrexone
Allocated to intervention (N=31)
• Received allocated intervention (N=31)
• Did not receive allocated intervention (N=0)
Valproate
Allocated to intervention (N=31)
• Received allocated intervention (N=31)
• Did not receive allocated intervention (N=0)
Lost to follow-up (N=8)
• Refused further assessment or withdrew (N=4)
• Illicit drug use (N=1)
• Became unreachable or left the city (N=2)
• Unknown reason (N=1)
Discontinued intervention (N=4)
•  Decided to discontinue the study medication 
but completed follow-up interviews (N=4)
Analyzed (N=31)
• Excluded from analysis (N=0)
Lost to follow-up (N=8)
• Withdrew (N=2)
• Illicit drug use (N=2)
• Elevation of liver transaminases (N=1)
• Unknown reason (N=3)
Discontinued intervention (N=2)
•  Decided to discontinue the study medication 
but completed follow-up interviews (N=2)
Analyzed (N=31)
• Excluded from analysis (N=0)
Excluded (N=228)
• Not eligible (N=181)
• Declined to participate (N=45)
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details on adverse events and criteria for early termination of
the study are presented in the online supplement.
Statistical Analysis
All randomly assigned participants were included for anal-
ysis, following the intention-to-treat principle. Time to re-
lapse to heavy drinking, the primary outcome, was compared
between the two study groups using the planned two-sample
log-rank test. The Kaplan-Meier curve was produced to
estimate the probability of remaining relapse free when
follow-up time elapsed. Unadjusted hazard ratio was esti-
mated from a Cox proportional hazards model that con-
trolled for study group (naltrexone versus valproate) only.
For sensitivity analysis, we obtained adjusted p value and
hazard ratio for the group effect in a Cox proportional
hazards model adjusted for site (Houston versus Iowa) as a
covariate and psychosocial treatment frequency (high versus
low) as strata, using the exact partial likelihood.
For secondary outcomes, time to first drinking was
compared between the two study groups using the log-rank
test. The percentage of drinking weeks was analyzed using
the generalized estimating equation with logit link and ex-
changeable working correlation, where the outcome was
binary and indicated whether the participant had any
drinking during each follow-up week.
As a secondary analysis, we tested a multivariate Cox
proportional hazards model for the primary outcome, with
study group, site, TBI severity, and PTSD status adjusted
as covariates and treatment frequency included as strata.
Baseline covariates that were unbalanced between the two
randomization groups were also controlled for. The effects
of TBI and PTSD were clinically important, as they repre-
sent frequent comorbidities in the veteran population whose
functional neuroanatomy overlaps with the circuits involved
in addiction. p values were based on the likelihood ratio test.
Secondary analyses were not adjusted for multiple com-
parisons, and results should be interpreted as exploratory.
The Cox proportional hazards assumption was tested and




We screened 290 male veterans enrolled for AUD re-
habilitation treatment at the Substance Use Disorders ser-
vices of the Iowa City VA Medical Center or the Michael E.
DeBakey VA Medical Center in Houston. A total of 62 pa-
tients were eligible and were randomly assigned to phar-
macological treatment between February 2012 and June
2015 (Figure 1).
Of the study subjects enrolled in Texas, 18 received nal-
trexone and 19 received valproate. Of the study subjects
enrolled in Iowa, 13 received naltrexone and 12 received
valproate. When randomly assigned, 46 (74%) participants
were also receiving intensive outpatient rehabilitation
treatment and 16 (26%) were followed by substance abuse
counselors on a weekly basis (i.e., high- and low-frequency
rehabilitation treatment, respectively).
Baseline Characteristics
The baseline characteristics of our study group are sum-
marized in Table 1. Baseline characteristics were well bal-
anced between the two groups, except that the percentage of
participants that lived by themselves was significantly
greater in the valproate group. The percentage of partici-
pants with no TBI, mild TBI, or moderate to severe TBI was
40.3%, 38.7% and 21.0%, respectively; 25.8% of the sample
had PTSD. The distribution of PTSD was similar among
those with and without TBI (24.3% versus 28%, odds ratio
[OR] 0.827, 95% CI=0.261–2.615, p=0.746).
Primary Outcome
During the follow-up period, nine study subjects in the
naltrexone group and 14 in the valproate group relapsed to
heavy drinking. Although the Kaplan-Meier survival curves
(Figure 2) showed a separation in relapse-free probability
between the two groups, the difference was not statistically
significant (log-rank x2=2.99, df=1, p=0.084). The unadjusted
hazard ratio for naltrexone versus valproate was 0.486 (95%
CI=0.209–1.130). The estimated probability of remaining
relapse free after 24 weeks of follow-up was 0.657 (95%
CI=0.436–0.809) in the naltrexone group and 0.441 (95%
CI=0.236–0.628) in the valproate group.
In sensitivity analysis, the adjusted hazard ratio for nal-
trexone versus valproate in the stratified Cox model was
0.436 (95% CI=0.180–1.056, likelihood ratio x2=3.55, df=1,
p=0.060).
Secondary Outcomes
Comparable results were obtained when comparing time
to first drinking (unadjusted hazard ratio=0.710, 95%
CI=0.373–1.350, log-rank x2=1.38, df=1, p=0.241) and the
percentage of drinking weeks (Wald x2=1.24, df=1, p=0.265)
between the two study groups, where the unadjusted odds
of drinking in the naltrexone group were 0.600 (95%
CI=0.245–1.474) times that in the valproate group. Conclu-
sions remained the same when we controlled for re-
habilitation treatment frequency and site.
Multivariate Analysis of the Primary Outcome
According to the multivariate Cox proportional hazards
model, participants with a history of moderate to severe TBI
were more likely to relapse into heavy drinking when com-
pared with those with no TBI (hazard ratio=4.834, 95%
CI=1.103–21.194, p=0.033). This was not the case for veterans
with a history of mild TBI (hazard ratio=1.669, 95%
CI=0.518, 5.380, p=0.385). PTSD status, on the other hand,
did not significantly affect outcome (hazard ratio=1.759, 95%
CI=0.605–5.116, p=0.300).
The model-based survival curve by randomization group
and the frequency of psychosocial treatment are shown in
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Figure 3. Participants who were enrolled in the inten-
sive outpatient treatment program were more likely to
avoid relapse into heavy drinking compared with those
participants who had one weekly session with their coun-
selor, independent of which pharmacological treatment they
received.
TABLE 1. Baseline characteristics of the study participantsa
Characteristic
Total (N=62) Valproate group (N=31) Naltrexone group (N=31)
pbMean or N SD or % Mean or N SD or % Mean or N SD or %
Age (years) (mean 6 SD) 47.4 9.2 46.7 9.6 48.1 8.8 0.662
Race/ethnicityc 0.349
White 33 54.1 17 54.8 16 53.3
African American 23 37.7 13 41.9 10 33.3
Other 5 8.2 1 3.2 4 13.3
Hispanic/Latino 5 8.2 3 9.7 2 6.7 1.000
Marital status 0.302
Single 24 38.7 12 38.7 12 38.7
Married 17 27.4 6 19.4 11 35.5
Divorced 19 30.6 11 35.5 8 25.8
Widowed 2 3.2 2 6.5 0 0
Employment 0.800
Full-time 17 27.4 10 32.3 7 22.6
Part-time 5 8.1 3 9.7 2 6.5
Volunteer work 1 1.6 1 3.2 0 0
Full-time student 3 4.8 1 3.2 2 6.5
Retired 1 1.6 0 0 1 3.2
Unemployed 24 38.7 10 32.3 14 45.2
Disabled 11 17.7 6 19.4 5 16.1
Living environment 0.007
Living independently 25 40.3 19 61.3 6 19.4
Living with nuclear family 14 22.6 5 16.1 9 29
Living with parents or close relatives 8 12.9 1 3.2 7 22.6
Living in a residential care facility or
group home
11 17.7 4 12.9 7 22.6
Homeless or living in a shelter 4 6.5 2 6.5 2 6.5
Maximum education level 0.595
Below or partial high school 3 4.8 1 3.2 2 6.5
High school graduate 18 29 7 22.6 11 35.5
Partial college ($1 year completed) 33 53.2 18 58.1 15 48.4
College education and above 8 12.9 5 16.1 3 9.7
Study site 0.796
Iowa City 25 40.3 12 38.7 13 41.9
Houston 37 59.7 19 61.3 18 58.1
HAM-D (mean 6 SD)c 10.1 5.8 10.1 4.2 10.1 7.1 0.413
HAM-A (mean 6 SD)d 10.5 4.3 10.6 3.8 10.4 4.8 0.659
YMS (mean 6 SD)e 2.7 3.9 2.5 2.6 2.9 4.9 0.470
AUDIT (mean 6 SD)f 24.4 7.7 23.9 6.6 25 8.9 0.617
TBI severity 0.739
No TBI 25 40.3 11 35.5 14 45.2
Mild 24 38.7 13 41.9 11 35.5
Moderate to severe 13 21.0 7 22.6 6 19.4
Number of TBIs (mean 6 SD) 1.4 1.5 1.6 1.6 1.2 1.4 0.268
Age at first TBI (years) (mean 6 SD)g 19.6 12.1 17.7 10.8 21.8 13.3 0.314
Current PTSD 16 25.8 9 29 7 22.6 0.562
PCL total (mean 6 SD)h 37.7 15.8 40 16.3 35.5 15.4 0.308
a AUDIT=Alcohol Use Disorders Identification Test, HAM-A=Hamilton Anxiety Rating Scale, HAM-D=Hamilton Depression Rating Scale, PCL=Posttraumatic
Stress Disorder Checklist, PTSD=posttraumatic stress disorder, TBI=traumatic brain injury, YMS=Young Mania Scale.
b For continuous variables, p values were based on two-sample t tests or Wilcoxon rank-sum test; p values for categorical variables were obtained using
Pearson’s chi-square test or Fisher’s exact test.
c Data were missing for one participant.
d Data were missing for five participants.
e Data were missing for two participants.
f Data were missing for eight participants.
g Data were missing for 25 participants.
h Data were missing for 12 participants.
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Compliance With Study Medication and Concurrent
Medication Use
Of 30 participants in the naltrexone group, six (20%) were
ever noncompliant with their study medication during the
follow-up. Of 31 participants in the valproate group, four
(12.9%) were ever noncompliant. There were no significant
differences between the valproate and the naltrexone groups
in the level of noncompliance with the study medication
(OR=1.688, 95% CI=0.425–6.704, Fisher’s exact p=0.508).
Similarly, no significant between-group difference was de-
tected in concurrent medication use (Table 2). Overall, the
percentages of participants who used concurrent medica-
tions were 69.4% for antidepressants, 8.1% for antianxiety
agents, 9.7% for antipsychotics, 8.1% for gabapentin, and
8.1% for prazosin.
In our group of participants treated with valproate, the
mean total valproate level was 42.7 mg/ml, the SD was 19.4
mg/ml, and the range varied from 9 to 72.7 mg/ml.
Adverse Events
There were no serious adverse events for any participant in
the trial. There were no significant differences between the
valproate or naltrexone groups in the frequency of adverse
events. However, valproate had more sedating effects than
naltrexone. The percentage of study subjects who had at
least one of the adverse events listed during the follow-up is
presented in Table 3.
DISCUSSION
The primary aim of this study was to test valproate’s efficacy
to reduce relapse to heavy drinking in a group of veterans
with AUD and neuropsychiatric comorbidities, including
TBI and PTSD. Survival analysis suggested no significant
difference between the two arms. As expected, participants
who were enrolled in an intensive outpatient program were
less likely to relapse into heavy drinking than participants
receiving a less intensive outpatient option, independent of
which pharmacological treatment they received.
Regarding the effect of coexistent neuropsychiatric con-
ditions, veterans with a history of moderate to severe TBI
were more likely to relapse into heavy drinking when com-
pared with veterans without TBI exposure. This increased
vulnerability was not observed among veterans with a his-
tory of mild TBI. On the other hand, a current diagnosis of
PTSD or the severity of anxiety, depressive, and PTSD
symptoms did not appear to affect treatment outcome. Fi-
nally, besides mild sedation, there were no significant dif-
ferences between the valproate and naltrexone groups in the
frequency of adverse events.
The principal limitation of the present study is related to
the relatively small sample size and, consequently, the lim-
ited power to identify subgroup differences. Though the
estimated relapse-free probability in the naltrexone group
was larger than that in the valproate group (Figure 2), the
difference was statistically nonsignificant. In fact, with the
estimated event rate and effect size in the current study, a
sample size of 164 is needed to detect the between-group
difference with 80% power. The study design did not include
a placebo arm because both investigators and reviewers of
FIGURE 2. Survival analysisa
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a The solid lines correspond to the Kaplan-Meier estimates, and dashed
lines represent the corresponding 95% confidence interval.
FIGURE 3. Effect of psychosocial treatment frequencya
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a The data were estimated from the multivariable Cox proportional
hazards model stratified by the frequency of rehabilitation treatment.
All other model covariates were set at the overall mean.
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the grant application considered it would be unethical to
give participants a placebo. The lack of a placebo control
restricts the interpretation of the results. In addition,
reliance on veterans’ self-report increases the possibility
of retrospective bias. Finally, considering valproate’s
teratogenic effects and the fact that most veterans en-
rolled in AUD programs are male, women were excluded
from the present study. This limits the generalizability of
the findings.
Given these limitations, what are the implications of these
findings? In first place, they support the idea that, in the
veteran population, an intensive outpatient program is more
efficacious that other less intensive psychosocial treatment
options. Furthermore, it has been suggested that an intensive
outpatient program might be
as effective as inpatient resi-
dential treatment (38).
Our findings suggest that
opiate antagonists may be
more effective than val-
proate to prevent relapse in-
to problematic alcohol use
among U.S. veterans. How-
ever, the present study is
underpowered to establish
this conclusively. It can be
argued that the study sub-
jects enrolled in our study
were closer to the phenotype
of reward drinkers driven by
positive reinforcement rather than relief drinkers among
whom negative reinforcement is a determinant factor (39).
However, most of these veterans were in advanced stages of
the addiction cycle, when negative reinforcement is more
prominent, and many had coexistent stress-related
psychopathology.
Alternatively, valproate may not be an efficacious modu-
lator of glutamatergic transmission, and other agents of this
kind may be more appropriate to treat addictive disorders in
this group of patients. However, a large and rigorous ran-
domized controlled trial reported that acamprosate (a
medication that influences glutamate synaptic homeostasis)
did not prevent relapse into heavy drinking, whereas nal-
trexone did (20).
Chronic AUD is charac-







connecting the PFC, the
striatum, and the extended
amygdala (41). Increased
excitatory input leads to
neuroplastic changes in
the amygdala, the nucleus
accumbens, and dorsal stria-




acid receptors and associated
with cravings and drug-
seeking behavior (42–44).
Pharmacological modifica-
tion of glutamatergic circuits
may result in a reduction of
these behavioral abnormalities.
TABLE 2. Concurrent medication by randomization group and type
Medicationa
Total Naltrexone group Valproate group Odds ratiob
pcN % N % N % Estimate 95% CI
Antidepressantsd 43 69.4 21 67.7 22 71.0 0.86 0.29–2.53 0.783
Antianxiety agentse 5 8.1 2 6.5 3 9.7 0.64 0.10–4.15 .0.9
Antipsychoticsf 6 9.7 3 9.7 3 9.7 1.00 0.19–5.39 .0.9
Gabapenting 5 8.1 2 6.5 3 9.7 0.64 0.10–4.15 .0.9
Prazosinh 5 8.1 3 9.7 2 6.5 1.55 0.24–10.01 .0.9
a The same participant may have taken more than one medication.
b Data represent odds ratios for the naltrexone group versus the valproate group.
c The p values were obtained using Pearson’s chi-square test or Fisher’s exact test.
d Antidepressants used were trazodone (N=22), citalopram (N=11), fluoxetine (N=10), sertraline (N=9), venlafaxine
(N=5), bupropion (N=5), and others (N=5).
e Antianxiety agents used were clonazepam (N=3), alprazolam (N=1), and buspirone (N=1).
f Antipsychotics used were quetiapine (N=2), perphenazine (N=1), risperidone (N=1), and aripiprazole (N=2).
g Five participants received gabapentin.
h Five participants received prazosin.








Abdominal pain 16.1 9.7 1.79 0.39–8.27 0.707
Anemia 3.2 0.0 – – .0.9
Bleeding 3.2 3.2 1.00 0.06–16.74 .0.9
Chest pain 6.5 3.2 2.07 0.18–24.07 .0.9
Confusion 12.9 12.9 1.00 0.23–4.42 .0.9
Diarrhea 29.0 32.3 0.86 0.29–2.53 0.783
Dizziness 25.8 22.6 1.19 0.37–3.82 0.767
Drowsiness 22.6 48.4 0.31 0.10–0.93 0.034
Hair loss 6.5 0.0 – – 0.492
Hypomania 3.2 6.5 0.48 0.04–5.62 .0.9
Insomnia 16.1 9.7 1.79 0.39–8.27 0.707
Lightheadedness 25.8 12.9 2.35 0.63–8.81 0.199
Nasal bleed 3.2 3.2 1.00 0.06–16.74 .0.9
Nasal inflammation 9.7 3.2 3.21 0.32–32.74 0.612
Nausea 29.0 9.7 3.82 0.92–15.81 0.054
Slowness of
movements
3.2 6.5 0.48 0.04–5.62 .0.9
Sweating 32.3 16.1 2.48 0.73–8.37 0.138
Tremor 12.9 6.5 2.15 0.36–12.69 0.671
Worsening depression 6.5 9.7 0.64 0.10–4.15 .0.9
Other 64.5 64.5 1.00 0.35–2.83 .0.9
a The data represent the odds ratio of each adverse event for the naltrexone group versus the valproate group; data
were not calculated for cohorts with 0%.
b The p values were obtained using Pearson’s chi-square test or Fisher’s exact test.
JNCN in Advance neuro.psychiatryonline.org 7
JORGE ET AL.
Specifically, valproate contributes to normalizing glutamate
neurotransmission through multiple mechanisms, including
blockade of sodium and voltage gated potassium channels, in-
creased GABAergic transmission, and the up-regulation of glu-
tamate transporters in astrocytes (45, 46). However, cravings are
also associated with an increase in the phasic activity of dopa-
minergic neurons ascending from the ventral tegmental area to
striatal and limbic targets. The increase in subcortical dopami-
nergic activity occurs in the context of faulty prefrontal regulation
and executive dysfunction (40). The striatal and limbic hyper-
dopaminergic state can be facilitated by opioid peptides and
consequently inhibited by opioid antagonists, explaining the
therapeutic action of naltrexone.
A history of moderate to severe TBI was associated with an
increased risk of relapse, probably associatedwith the prefrontal
dysfunction characteristic of this condition. Both TBI and ad-
dictive disorders demonstrate prefrontal cortex abnormalities
and may lead to disruption of neural circuits that, originating
from the PFC and basolateral amygdala, converge in the ventral
striatum. These additive changesmay lead to to relapse to heavy
drinking following a period of abstinence (47–49). Thus, they
may play an important etiological role in the development of
more severe and treatment refractory forms of AUD.
It is also well known that stress and negative affect may
precipitate relapse into heavy drinking (50). However, we
did not observe a clear-cut indication that such mechanisms
played a decisive role in determining relapse in our group
of veterans. For instance, PTSD status and the severity of
depressive and anxiety symptoms were not associated
with increased likelihood of relapse.
In summary, intensive outpatient programs constitute an
efficacious alternative to treat AUD among U.S. veterans.
However, the role of pharmacological treatment is not
completely elucidated. Glutamatergic agents appear to be
less effective than opiate antagonists to prevent relapse into
heavy drinking and to increase cumulative abstinence. Fu-
ture studies need to examine new pharmacological and
nonpharmacological options, including noninvasive brain
stimulation techniques. Furthermore, we need to identify
subgroups of alcoholic patients that may respond to a spe-
cific form of treatment but not to others (e.g., study subjects
with a history of moderate to severe TBI or study subjects
with known genetic polymorphisms of opiate receptors).
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